**Question for written answer E-006212/2014**
**to the Commission**
Rule 130
**Philippe Juvin (PPE)**

Subject: Medical use of nanoparticles

The global markets for direct and indirect applications of nanotechnologies and synthetic biology are expected to be worth USD 3 000 billion and USD 10 000 billion respectively over the period to 2025. These technologies have been identified by the Commission as key enabling technologies. However, there are still obstacles to their development, in particular public concerns about the risks involved, our as yet sketchy knowledge of precisely what these technologies can do and uncertainty about the way the regulatory environment will develop, and this is discouraging private investment.

French researchers at ESPCI ParisTech recently demonstrated the effectiveness of a bonding method which uses aqueous solutions of nanoparticles (silica, iron oxides) to repair tissue, aid wound healing and repair injuries to organs that are soft and difficult to suture, such as the liver.

1. Will the Commission provide specific support under the Horizon 2020 programme for the development of European clinical research into the use of nanoparticles for wound healing and tissue regeneration?

2. How does it intend to support more broadly end-to-end product development of nanotechnologies for the healthcare sector in the EU?

3. What kind of regulatory framework does the Commission intend to introduce to govern the use of nanomaterials, with a view to winning over the public and encouraging investment?